+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
FEMALE
ID06856499

Phase 1 Study of Cirtuvivint and Olaparib Combination Therapy in Women with BRCA or HRD Positive Platinum Resistant Ovarian Cancer

Led by University of Colorado, Denver · Updated on 2026-07-24

50

Participants Needed

2

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of a combination treatment using Cirtuvivint and Olaparib in women with platinum-resistant ovarian cancer that is high-grade serous or endometrioid epithelial type, including primary peritoneal and fallopian tube cancers. This phase I trial aims to find the recommended dose of this combination therapy for patients who have tested positive for BRCA mutations or homologous recombination deficiency HRD and have had no more than three prior lines of therapy including prior PARP inhibitor treatment. Participants receive Olaparib orally twice daily at a standard dose of 300 mg, combined with Cirtuvivint taken orally either 5 days on and 2 days off at 80 mg or 2 days on and 5 days off at 120 mg in alternating cohorts. The treatment cycles last 28 days, and participants follow one of these two dosing schedules depending on their assigned cohort. The study involves repeated treatment cycles and monitoring over time to determine the safety and optimal dosing. During the trial, participants will visit the clinic frequently in the first two months for physical exams, blood tests, vital signs, and other care procedures, then continue visits every 28 days thereafter. Researchers will assess safety and tolerability over 6 months and measure drug levels and clearance over 3 years. Participants health status, lab tests, and disease progression will be monitored closely throughout the study, which may continue until study completion or withdrawal.

CONDITIONS

Brief Title

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Research Team

K

Kailey Palmen, BA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here